CN111632057A - Application of rhamnose monosulfate trisaccharide and derivatives in skeletal muscle atrophy resistance - Google Patents
Application of rhamnose monosulfate trisaccharide and derivatives in skeletal muscle atrophy resistance Download PDFInfo
- Publication number
- CN111632057A CN111632057A CN202010529096.6A CN202010529096A CN111632057A CN 111632057 A CN111632057 A CN 111632057A CN 202010529096 A CN202010529096 A CN 202010529096A CN 111632057 A CN111632057 A CN 111632057A
- Authority
- CN
- China
- Prior art keywords
- monosulfate
- skeletal muscle
- rhamnostriose
- rhamnose
- muscle atrophy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000026214 Skeletal muscle atrophy Diseases 0.000 title claims abstract description 30
- 230000025185 skeletal muscle atrophy Effects 0.000 title claims abstract description 30
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 title claims description 41
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 title claims description 41
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 title claims description 41
- 150000004043 trisaccharides Chemical class 0.000 title claims description 10
- 210000002027 skeletal muscle Anatomy 0.000 claims abstract description 15
- 210000004027 cell Anatomy 0.000 claims abstract description 11
- 239000003814 drug Substances 0.000 claims abstract description 11
- 102000004364 Myogenin Human genes 0.000 claims abstract description 9
- 108010056785 Myogenin Proteins 0.000 claims abstract description 9
- 230000004069 differentiation Effects 0.000 claims abstract description 9
- 235000013376 functional food Nutrition 0.000 claims abstract description 9
- 210000002363 skeletal muscle cell Anatomy 0.000 claims abstract description 9
- 102000003505 Myosin Human genes 0.000 claims abstract description 6
- 108060008487 Myosin Proteins 0.000 claims abstract description 6
- 230000005764 inhibitory process Effects 0.000 claims abstract description 6
- 230000001114 myogenic effect Effects 0.000 claims abstract description 6
- 210000001087 myotubule Anatomy 0.000 claims abstract description 6
- 238000000034 method Methods 0.000 claims description 17
- 241000196252 Ulva Species 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 239000007864 aqueous solution Substances 0.000 claims description 8
- 241000989762 Monostroma nitidum Species 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- 239000006228 supernatant Substances 0.000 claims description 6
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 claims description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- 238000011033 desalting Methods 0.000 claims description 4
- 239000003480 eluent Substances 0.000 claims description 4
- 238000010828 elution Methods 0.000 claims description 4
- 238000004108 freeze drying Methods 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 230000001376 precipitating effect Effects 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 238000002144 chemical decomposition reaction Methods 0.000 claims description 3
- 230000000593 degrading effect Effects 0.000 claims description 3
- 230000007935 neutral effect Effects 0.000 claims description 3
- OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 3
- 238000000108 ultra-filtration Methods 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 abstract description 11
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract description 11
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract description 11
- 230000009466 transformation Effects 0.000 abstract description 5
- 230000001737 promoting effect Effects 0.000 abstract description 4
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 11
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 10
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 201000000585 muscular atrophy Diseases 0.000 description 8
- 238000004113 cell culture Methods 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 4
- 238000001819 mass spectrum Methods 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 230000004220 muscle function Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- WFIYPADYPQQLNN-UHFFFAOYSA-N 2-[2-(4-bromopyrazol-1-yl)ethyl]isoindole-1,3-dione Chemical compound C1=C(Br)C=NN1CCN1C(=O)C2=CC=CC=C2C1=O WFIYPADYPQQLNN-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 208000002720 Malnutrition Diseases 0.000 description 2
- 102000008934 Muscle Proteins Human genes 0.000 description 2
- 108010074084 Muscle Proteins Proteins 0.000 description 2
- 206010028289 Muscle atrophy Diseases 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000001071 malnutrition Effects 0.000 description 2
- 235000000824 malnutrition Nutrition 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000020763 muscle atrophy Effects 0.000 description 2
- 208000015380 nutritional deficiency disease Diseases 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 1
- 239000002083 C09CA01 - Losartan Substances 0.000 description 1
- 241000195628 Chlorophyta Species 0.000 description 1
- 101800000414 Corticotropin Proteins 0.000 description 1
- 102100038019 Corticotropin-releasing factor receptor 2 Human genes 0.000 description 1
- 101150081899 Crhr2 gene Proteins 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000893951 Monostroma Species 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- JKWKMORAXJQQSR-MOPIKTETSA-N Nandrolone Decanoate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCCCCCCC)[C@@]1(C)CC2 JKWKMORAXJQQSR-MOPIKTETSA-N 0.000 description 1
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 1
- 229940079156 Proteasome inhibitor Drugs 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 238000005034 decoration Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002638 denervation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
- 229960004773 losartan Drugs 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 229960001935 nandrolone decanoate Drugs 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- CTYRPMDGLDAWRQ-UHFFFAOYSA-N phenyl hydrogen sulfate Chemical compound OS(=O)(=O)OC1=CC=CC=C1 CTYRPMDGLDAWRQ-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000003207 proteasome inhibitor Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000008264 rhamnoses Chemical class 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/06—Separation; Purification
- C07H1/08—Separation; Purification from natural products
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The embodiment of the invention provides application of rhamnostriose monosulfate and derivatives thereof in skeletal muscle atrophy resistance, and the rhamnostriose monosulfate or the rhamnostriose monosulfate derivatives are applied to a medicament for resisting skeletal muscle atrophy, or the rhamnostriose monosulfate derivatives are applied to a functional food for resisting skeletal muscle atrophy. The rhamnostriose monosulfate is used for inhibiting the differentiation inhibition of TNF-alpha on skeletal muscle cells C2C12, promoting the generation of myosin MHC and myogenin of C2C12 and promoting the transformation of skeletal muscle myogenic cells into muscle fibers.
Description
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to an application of rhamnose monosulfate and a derivative thereof in skeletal muscle atrophy resistance.
Background
Skeletal muscle atrophy (abbreviated as muscular atrophy) mainly refers to the reduction of skeletal muscle mass and muscle function, the occurrence of muscular atrophy is the comprehensive expression of negative balance of degradation and synthesis of skeletal muscle protein, and influencing factors comprise related hormone change, active oxygen tissue level change, apoptosis and the like. Common causes of muscular atrophy include long-term malnutrition, loss or lack of movement of the systemic or local limbs, denervation, etc., and finding out and removing pathogenic causes is an important prerequisite for the treatment and prevention of diseases. Skeletal muscle atrophy caused by long-term malnutrition can be gradually improved under the conditions of removing causes and continuously supplementing comprehensive nutrition. The catabolism and synthesis of skeletal muscle proteins are influenced and regulated by a number of hormones, cytokines, proteasome inhibitors in the body. Aiming at the condition of reducing anabolic regulator substances, the method for preventing and treating muscular atrophy by supplementing a proper amount of growth factors is an effective method. In addition to insulin growth factor, recombinant human growth hormone (rhGH), adrenocorticotropic hormone releasing factor 2 receptor (CRF2R) agonist, nandrolone decanoate, creatine, losartan, vitamin D, leucine and the like, in recent years, research reports that vitamin E, resveratrol and mitochondrial nutrients have good antagonistic effect on animal muscle atrophy. The medicines respectively show different control effects on different forms of muscular atrophy, experimental animals of different months of age or people of different ages. However, no report is found at present on the research of rhamnose sulfate in resisting muscular atrophy.
Disclosure of Invention
The invention aims to provide application of rhamnose monosulfate and derivatives thereof in resisting skeletal muscle atrophy.
In order to achieve the purpose, the invention adopts the following technical scheme:
one aspect of the invention provides the use of rhamnotrise monosulfate in the treatment of skeletal muscle atrophy.
Another aspect of the present invention provides the use of a rhamnotrisaccharide monosulfate derivative for the treatment of skeletal muscle atrophy.
Optionally, the rhamnostriose monosulfate or the rhamnostriose monosulfate derivative is applied to a medicament for resisting skeletal muscle atrophy, or the rhamnostriose monosulfate derivative is applied to a functional food for resisting skeletal muscle atrophy.
Optionally, the rhamnotrise monosulfate is used for inhibiting the differentiation inhibition of TNF-alpha on skeletal muscle cell C2C12, promoting the generation of myosin MHC and myogenin of C2C12 and promoting the transformation of skeletal muscle myogenic cells into muscle fibers.
Optionally, the rhamnose monosulfate trisaccharide is prepared by taking green alga monostroma nitidum or enteromorpha as a raw material and performing chemical degradation, ultrafiltration and gel column separation; the molecular structure of the compound is alpha-L-Rhap- (2S04) - (1 → 3) -alpha-L-Rhap, the compound is formed by connecting a 1, 3 glycosidic bond with rhamnose (Rha) bond, and the molecular weight is 536.14 Da.
Optionally, the molecular structural formula of the rhamnostriose monosulfate is as follows:
optionally, the rhamnostriose monosulfate derivative includes: the method comprises the steps of using a sulfated derivative containing rhamnostriose monosulfate as a mother core, using a phosphorylated derivative containing rhamnostriose monosulfate as a mother core, and using an acetylated derivative containing rhamnostriose monosulfate as a mother core.
Optionally, the dosage of the rhamnose monosulfate is 10-300 mg/kg.
Optionally, the preparation method of the rhamnostriose monosulfate comprises the following steps:
1) preparing the green alga monostroma nitidum or the enteromorpha into an aqueous solution;
2) adding dilute hydrochloric acid into the aqueous solution obtained in the step 1), heating, stirring, degrading, and adjusting the pH value to be neutral by adopting NaOH;
3) concentrating and precipitating the solution obtained in the step 2) with ethanol, concentrating the supernatant by a rotary instrument, and desalting by a gel chromatographic column;
4) then separating and purifying by adopting a Bio-Gel P4 chromatographic column, detecting the sugar content of the eluent by a sulfuric acid phenol method, and drawing an elution curve;
5) and collecting the peak part, and freeze-drying to obtain the rhamnose monosulfate.
The invention has the beneficial effects that:
1. the invention provides application of rhamnose monosulfate and derivatives in skeletal muscle atrophy resistance.
2. In the embodiment of the invention, the rhamnostriose monosulfate or the rhamnostriose monosulfate derivative is applied to a medicament for resisting skeletal muscle atrophy, or the rhamnostriose monosulfate derivative is applied to a functional food for resisting skeletal muscle atrophy.
3. The embodiment of the invention adopts a cell model of TNF-alpha induced skeletal muscle atrophy, and finds the application of the rhamnostriose monosulfate in resisting the skeletal muscle atrophy. The experimental results show that: the rhamnose monosulfate can obviously inhibit the differentiation inhibition of TNF-alpha on skeletal muscle cell C2C 12; and effectively promotes the generation of myosin MHC and myogenin of C2C12, effectively promotes the transformation of skeletal muscle myogenic cells to muscle fibers, and has obvious effect of resisting skeletal muscle atrophy.
4. The raw materials of the embodiment of the invention are derived from marine natural green algae reef membranes or enteromorpha, have the advantages of rich resources, easy industrialization, safety, effectiveness and the like, and can be developed into medicines and functional foods (health care products) for resisting skeletal muscle atrophy, thereby having better market application prospect.
Drawings
FIG. 1 is a secondary mass spectrum of rhamnostriose monosulfate in the example of the present invention.
Detailed Description
The conception, the specific structure, and the technical effects produced by the present invention will be clearly and completely described in conjunction with the embodiments below, so that the objects, the features, and the effects of the present invention can be fully understood. It is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all embodiments, and those skilled in the art can obtain other embodiments without inventive effort based on the embodiments of the present invention, and all embodiments are within the protection scope of the present invention.
One embodiment of the invention provides the use of rhamnotrise monosulfate to combat skeletal muscle atrophy.
Specifically, the rhamnose monosulfate trisaccharide is applied to a medicament or functional food for resisting skeletal muscle atrophy.
The specific application mode is as follows: the rhamnose monosulfate trisaccharide can be directly taken as a medicine or a functional food.
The specific usage and dosage are as follows: the dosage of the rhamnose monosulfate is 20-750mg per time, 1-3 times per day. The dosage of the rhamnostriose monosulfate is 10-300 mg/kg.
In the embodiment of the invention, the rhamnostriose monosulfate can inhibit the differentiation inhibition of TNF-alpha on skeletal muscle cell C2C12, promote the generation of myosin MHC and myogenin of C2C12, promote the transformation of skeletal muscle myogenic cells to muscle fibers and have obvious effect of resisting skeletal muscle atrophy.
Another embodiment of the present invention provides the use of a rhamnotrise monosulfate derivative for the treatment of skeletal muscle atrophy.
Specifically, the rhamnose monosulfate trisaccharide derivative is applied to a medicament or functional food for resisting skeletal muscle atrophy.
The specific application mode is as follows: the rhamnose monosulfate trisaccharide derivative can be directly taken as a medicine or a functional food.
The specific usage and dosage are as follows: the dosage of the rhamnose monosulfate is 20-750mg per time, 1-3 times per day. The dosage of the rhamnostriose monosulfate is 10-300 mg/kg.
In the embodiment of the invention, the rhamnostriose monosulfate derivative can inhibit the differentiation inhibition of TNF-alpha on skeletal muscle cells C2C12, promote the generation of myosin MHC (major histocompatibility complex) and myogenin of C2C12, promote the transformation of skeletal muscle myogenic cells to muscle fibers and have obvious effect of resisting skeletal muscle atrophy.
In the embodiment of the invention, the rhamnostriose monosulfate derivative comprises the following components: the method comprises the steps of using a sulfated derivative containing rhamnostriose monosulfate as a mother core, using a phosphorylated derivative containing rhamnostriose monosulfate as a mother core, and using an acetylated derivative containing rhamnostriose monosulfate as a mother core.
Yet another embodiment of the invention provides rhamnotrise monosulfate and a preparation method thereof
The rhamnose monosulfate trisaccharide is prepared by taking green alga Monostroma nitidum or Enteromorpha as a raw material through chemical degradation, ultrafiltration and a gel column separation method; the molecular structure of the compound is alpha-L-Rhap- (2S04) - (1 → 3) -alpha-L-Rhap, the compound is formed by connecting a 1, 3 glycosidic bond with rhamnose (Rha) bond, and the molecular weight is 536.14 Da.
The preparation method of the rhamnostriose monosulfate comprises the following steps:
1) preparing the green alga monostroma nitidum or the enteromorpha into 0.5-1.5 wt% of water solution;
2) adding 0.2-1.0 wt% of dilute hydrochloric acid into the aqueous solution obtained in the step 1), heating to 80-100 ℃, stirring to degrade the aqueous solution for 4-6 hours, and adjusting the pH value to be neutral by adopting NaOH;
3) concentrating and precipitating the solution obtained in the step 2) with ethanol, concentrating the supernatant by a rotary instrument, and desalting by a gel chromatographic column Sephadex G10;
4) then separating and purifying by adopting a Bio-Gel P4 chromatographic column, detecting the sugar content of the eluent by a sulfuric acid phenol method, and drawing an elution curve;
5) and collecting the peak part, and freeze-drying to obtain the rhamnose monosulfate.
The following are specific examples.
Example 1
Preparing green alga enteromorpha algae powder into a 1 wt% aqueous solution, adding 0.5 wt% diluted hydrochloric acid into the enteromorpha aqueous solution, heating to 90 ℃, stirring and degrading for 5 hours, neutralizing with 0.1M NaOH to obtain pH7.0, concentrating, precipitating with ethanol, concentrating the supernatant by a rotary instrument, desalting by a Gel chromatographic column Sephadex G10, separating and purifying by a Bio-Gel P4 Gel chromatographic column, detecting the sugar content of the eluent by a phenol sulfate method, drawing an elution curve, collecting the peak part, and freeze-drying to obtain the rhamnose monosulfate.
The structural formula of the prepared rhamnostriose monosulfate is as follows:
an oligosaccharide sample (rhamnose monosulfate) was reacted with 0.05mol/l NaBH4 at 4 ℃ for 10 hours in a refrigerator, and the pH was adjusted to 7.0 with acetic acid water. The oligosaccharide sample was eluted with distilled water using AG50W-X8 column, then concentrated and lyophilized. In the mass spectrometry process, nitrogen is used as a blow-dry gas and a spray gas, the flow rate is 250L/h, and acetonitrile and water are used as a mobile phase at a ratio of 1: 1(V/V) for performing the analysis of the quality. In the secondary mass spectrum, the cone hole voltage is 80eV, argon is used as collision gas, and the flow rate is 15L/h. At the same time, the best sequence information is obtained while maintaining the collision energy exchanged at 20-50 eV. The ion source and solvent volatilization peak temperatures were 80 ℃ and 150 ℃, respectively.
According to a secondary mass spectrum of the monosulfated rhamnose, MS/MS fragment ions (m/z 225) (m/z243) (m/z371) (m/z 389) are generated by the breakage of glycosidic bonds, and the fragment ions (m/z 475) determine that a sulfate group is positioned at the C-2 position of rhamnose at the non-reducing end. According to the sequence analysis method of the rhamnose sulfate secondary mass spectrum, the structure of the rhamnose sulfate is deduced to be alpha-L-Rhap- (2S04) - (1 → 3) -alpha-L-Rhap.
Experimental test 1: effect of rhamnose monosulfate on TNF-alpha induced Release of LDH from skeletal muscle cells
The test was carried out using the rhamnostriose monosulfate prepared in example 1. The method comprises the following specific steps:
(1) cell culture: C2C12 cells were inoculated into DMEM complete medium (containing 100U/mL penicillin, 100U/mL streptomycin and 10% FBS) and cultured in a 5% CO2 incubator at 37 ℃.
(2) 8000 cells per hole are planted in a 96-hole plate, the 96-hole plate is placed in a constant-temperature cell culture box to be incubated for 12 hours, then, rhamnose monosulfate with different concentrations is added, and the 96-hole plate is placed in the constant-temperature cell culture box to be incubated for 12 hours continuously. After the incubation is finished, the culture medium is replaced, 100ng/ml of TNF-alpha is added into each hole, after the incubator is incubated for 48 hours, the supernatant is collected, and the LDH content in the supernatant is detected. Each time three replicates were performed and the experiment was repeated three times.
The experimental results are shown in Table 1, when the monostroma oligodisaccharide is administered at the concentrations of 50 mu mol/L, 100 mu mol/L and 200 mu mol/L, and 400 mu mol/L, the release level of LDH is significantly different from that of a control group, and the rhamnostriose monosulfate can significantly inhibit the release of TNF-alpha induced LDH in skeletal muscle cells and has obvious dose-dependent effect.
TABLE 1 Effect of rhamnostriose monosulfate on TNF- α induced LDH release from skeletal muscle cells
Group (mu mol/L) | LDH release levels |
Control group | 1.0±0.02 |
Model set | 2.1±0.02# |
50 | 1.8±0.01* |
100 | 1.6±0.03* |
200 | 1.4±0.02 |
400 | 1.2±0.01* |
Note: n is 9, x ± SD, P < 0.05, P < 0.001 compared to the model group
Experimental test 2: effect of rhamnostriose monosulfate on TNF- α -induced skeletal muscle differentiation protein the effect of rhamnostriose monosulfate on TNF- α -induced skeletal muscle differentiation protein was tested using the rhamnostriose monosulfate prepared in example 1.
(1) Cell culture: C2C12 cells were inoculated in DMEM complete medium (containing 1OOU/mL penicillin, 100U/mL streptomycin and 10% FBS) and cultured in a 5% CO2 incubator at 37 ℃.
(2) 8000 cells per hole are planted in a 96-hole plate, the 96-hole plate is placed in a constant-temperature cell culture box to be incubated for 12 hours, then, rhamnose monosulfate with different concentrations is added, and the 96-hole plate is placed in the constant-temperature cell culture box to be incubated for 12 hours continuously. And (3) after the incubation is finished, replacing the culture medium, adding 100ng/ml of TNF-alpha into each hole, continuously incubating in an incubator for 72 hours, extracting RNA, and performing fluorescent quantitative RT-PCR analysis on mRNA of MHC (major histocompatibility complex) and myogenin. The experiment was repeated three times.
The results are shown in table 2, and rhamnose monosulfate can significantly reverse the expression of TNF-alpha inhibited myofibrillar key proteins. The rhamnose monosulfate can obviously improve the expression of MHC (major histocompatibility complex) and increase the protein content of Myogenin. MHC and Myogenin are important indexes for measuring skeletal muscle function, and the expression level is obviously reduced in muscle atrophy diseases, so that the skeletal muscle function is degraded. The rhamnose monosulfate in the embodiment of the invention can effectively inhibit muscle damage and protect skeletal muscle from being interfered by diseases.
TABLE 2 Effect of rhamnostriose monosulfate on TNF- α induced skeletal muscle differentiation protein
It should be noted that, throughout the specification, the terms "comprises," "comprising," or any other variation thereof, are intended to cover a non-exclusive inclusion, such that a process, method, article, or apparatus that comprises a list of elements does not include only those elements but may include other elements not expressly listed or inherent to such process, method, article, or apparatus.
The principles and embodiments of the present invention are explained herein using specific examples, which are presented only to assist in understanding the method and its core concepts of the present invention. It should be noted that there are no more than infinite trial-and-error modes objectively due to the limited character expressions, and it will be apparent to those skilled in the art that various modifications, decorations, or changes may be made without departing from the spirit of the invention or the technical features described above may be combined in a suitable manner; such modifications, variations, combinations, or adaptations of the invention using its spirit and scope, as defined by the claims, may be directed to other uses and embodiments.
Claims (9)
1. Application of rhamnose monosulfate trisaccharide in resisting skeletal muscle atrophy.
2. Application of the rhamnose monosulfate trisaccharide derivative in resisting skeletal muscle atrophy.
3. The use according to claim 1 or 2, characterized in that the rhamnostriose monosulfate or the rhamnostriose monosulfate derivative is applied in a medicament against skeletal muscle atrophy or in a functional food against skeletal muscle atrophy.
4. The use according to any of claims 1 to 3, wherein the rhamnotrisaccharide monosulfate is used to inhibit the inhibition of the differentiation of TNF- α on skeletal muscle cells C2C12, and to promote the production of C2C12 myosin MHC and myogenin, and the conversion of skeletal muscle myogenic cells into muscle fibers.
5. The application of claim 4, wherein the rhamnostriose monosulfate is prepared by taking green alga Monostroma nitidum or Enteromorpha as a raw material through chemical degradation, ultrafiltration and a gel column separation method; the molecular structure of the compound is alpha-L-Rhap- (2S04) - (1 → 3) -alpha-L-Rhap, the compound is formed by connecting a 1, 3 glycosidic bond with rhamnose (Rha) bond, and the molecular weight is 536.14 Da.
7. the use according to claim 2, characterized in that said rhamnose monosulfate derivative comprises: the method comprises the steps of using a sulfated derivative containing rhamnostriose monosulfate as a mother core, using a phosphorylated derivative containing rhamnostriose monosulfate as a mother core, and using an acetylated derivative containing rhamnostriose monosulfate as a mother core.
8. The use according to claim 1 or 2, characterized in that the rhamnose monosulfate is used in an amount of 10-300 mg/kg.
9. The use according to claim 1 or 2, characterized in that the preparation process of the rhamnostriose monosulfate comprises the following steps:
1) preparing the green alga monostroma nitidum or the enteromorpha into an aqueous solution;
2) adding dilute hydrochloric acid into the aqueous solution obtained in the step 1), heating, stirring, degrading, and adjusting the pH value to be neutral by adopting Na 0H;
3) concentrating and precipitating the solution obtained in the step 2) with ethanol, concentrating the supernatant by a rotary instrument, and desalting by a gel chromatographic column;
4) then separating and purifying by adopting a Bio-Gel P4 chromatographic column, detecting the sugar content of the eluent by a sulfuric acid phenol method, and drawing an elution curve;
5) and collecting the peak part, and freeze-drying to obtain the rhamnose monosulfate.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010529096.6A CN111632057A (en) | 2020-06-10 | 2020-06-10 | Application of rhamnose monosulfate trisaccharide and derivatives in skeletal muscle atrophy resistance |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010529096.6A CN111632057A (en) | 2020-06-10 | 2020-06-10 | Application of rhamnose monosulfate trisaccharide and derivatives in skeletal muscle atrophy resistance |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111632057A true CN111632057A (en) | 2020-09-08 |
Family
ID=72323458
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010529096.6A Pending CN111632057A (en) | 2020-06-10 | 2020-06-10 | Application of rhamnose monosulfate trisaccharide and derivatives in skeletal muscle atrophy resistance |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111632057A (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101091713A (en) * | 2006-06-19 | 2007-12-26 | 深圳市牌牌科技有限公司 | Tripterine capsule in use for preventing and treating disease of nerve damage, preparation method and usage |
CN102993244A (en) * | 2012-11-26 | 2013-03-27 | 中国海洋大学 | Oligorhamnose monomer and preparation method thereof |
CN104586878A (en) * | 2015-01-14 | 2015-05-06 | 青岛海洋生物医药研究院股份有限公司 | Fucoidan sulfate and application of low-molecular-weight fucoidan sulfate in preparation of metabolic syndrome resistant medicines and health products |
JP2019024467A (en) * | 2017-08-03 | 2019-02-21 | 株式会社明治 | Manufacture method of chronic inflammation non-human model animal for evaluating skeletal muscle rehabilitation effect, and evaluation method of skeletal muscle rehabilitation auxiliary effect of test substance using the same |
-
2020
- 2020-06-10 CN CN202010529096.6A patent/CN111632057A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101091713A (en) * | 2006-06-19 | 2007-12-26 | 深圳市牌牌科技有限公司 | Tripterine capsule in use for preventing and treating disease of nerve damage, preparation method and usage |
CN102993244A (en) * | 2012-11-26 | 2013-03-27 | 中国海洋大学 | Oligorhamnose monomer and preparation method thereof |
CN104586878A (en) * | 2015-01-14 | 2015-05-06 | 青岛海洋生物医药研究院股份有限公司 | Fucoidan sulfate and application of low-molecular-weight fucoidan sulfate in preparation of metabolic syndrome resistant medicines and health products |
JP2019024467A (en) * | 2017-08-03 | 2019-02-21 | 株式会社明治 | Manufacture method of chronic inflammation non-human model animal for evaluating skeletal muscle rehabilitation effect, and evaluation method of skeletal muscle rehabilitation auxiliary effect of test substance using the same |
Non-Patent Citations (1)
Title |
---|
HONGYAN LI 等: "Sequence analysis of the sulfated rhamno-oligosaccharides derived from a sulfated rhamnan", 《CARBOHYDRATE POLYMERS》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2020177390A1 (en) | Method for preparing l-ergothioneine-containing cosmetic stock solution by means of fermenting hericium erinaceus | |
CN105132491B (en) | A kind of extracting method of pachymaran | |
CN104987316A (en) | Marine fungus-derived polyketone compound and application thereof in treatment of type 2 diabetes | |
CN111888359A (en) | Application of pyrroloquinoline quinone in anti-asthma and anti-allergic medicines | |
CN109749941B (en) | Paecilomyces cicadae fermentation medium and method for preparing ergosterol by fermenting Paecilomyces cicadae | |
CN113197258B (en) | Selenium-rich vine tea and preparation method thereof | |
CN105559068A (en) | Composition obtained by fermenting tetrastigma hemsleyanum diels et gilg. through edible and medicinal fungi and preparation method of composition | |
CN105695350B (en) | Saccharomyces cerevisiae and method for producing glucosamine by using saccharomyces cerevisiae | |
CN111632057A (en) | Application of rhamnose monosulfate trisaccharide and derivatives in skeletal muscle atrophy resistance | |
CN1533776A (en) | Application of N-acetly glucosamine in the preparation of medicine for treating local injury and full body syndrome due to virus or bacterial infestation | |
CN111867402A (en) | Agaricus campestris composite mycelium composition with liver function improving activity and its preparation method | |
CN114468150B (en) | Application of gentisic acid in promoting growth and rumen development of young ruminants | |
CN111150754B (en) | Application of chestnut flower extract in preparation of food or anti-inflammatory drugs | |
CN104988083B (en) | Streptomyces platensis and its application in terms of producing plate mycin peace laminin | |
CN102219720A (en) | Novel selenic acid biological material with anti-aging function | |
CN111773323A (en) | Application of dendrobium water extract in treating type 2 diabetes | |
CN106421455B (en) | Sweet sorghumus extract and preparation method and application thereof | |
CN107281255B (en) | Robinia pseudoacacia leaf active part and preparation method and application thereof | |
CN111789252A (en) | Method for improving kidney-tonifying and yang-strengthening effects of maca by enzymolysis fermentation method | |
CN116023423B (en) | Ginsenoside Rk3 and preparation and application thereof in preparation of folliculitis medicines | |
KR20140072418A (en) | Composition for Improving Obesity | |
CN115286682B (en) | 3-O-arabinosyl mesitylene Liu Suanzao glycoside and preparation method and application thereof | |
KR20200016610A (en) | Composition for Improvement of Fatty Liver | |
CN115433703B (en) | Application of capsaicin in promoting proliferation of akkermansia muciniphila | |
CN110882263B (en) | Application of Monostroma nitidum oligosaccharose in preparing anti-breast cancer medicine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200908 |
|
RJ01 | Rejection of invention patent application after publication |